

Antimicrobial Effects of Antipyretics

Petra Zimmermann^{a,b,c} Nigel Curtis^{a,b,c}

Department of Paediatrics, The University of Melbourne, Parkville, Australia^a; Infectious Diseases & Microbiology Research Group, Murdoch Children's Research Institute, Parkville, Australia^b; Infectious Diseases Unit, The Royal Children's Hospital Melbourne, Parkville, Australia^c

ABSTRACT Antipyretics are some of the most commonly used drugs. Since they are often coadministered with antimicrobial therapy, it is important to understand the interactions between these two classes of drugs. Our review is the first to summarize the antimicrobial effects of antipyretic drugs and the underlying mechanisms involved. Antipyretics can inhibit virus replication, inhibit or promote bacterial or fungal growth, alter the expression of virulence factors, change the surface hydrophobicity of microbes, influence biofilm production, affect the motility, adherence, and metabolism of pathogens, interact with the transport and release of antibiotics by leukocytes, modify the susceptibility of bacteria to antibiotics, and induce or reduce the frequency of mutations leading to antimicrobial resistance. While antipyretics may compromise the efficacy of antimicrobial therapy, they can also be beneficial, for example, in the management of biofilm-associated infections, in reducing virulence factors, in therapy of resistant pathogens, and in inducing synergistic effects. In an era where it is becoming increasingly difficult to find new antimicrobial drugs, targeting virulence factors, enhancing the efficacy of antimicrobial therapy, and reducing resistance may be important strategies.

KEYWORDS NSAIDs, ibuprofen, acetaminophen, paracetamol, antibacterial, antimicrobial, efflux pumps

Acetaminophen (paracetamol), acetylsalicylic acid (ASA; aspirin, which is rapidly degraded to salicylic acid [SAL] *in vivo*), and other nonsteroidal anti-inflammatory drugs (NSAIDs), such as diclofenac, flurbiprofen, ibuprofen, and indomethacin, are some of the most commonly used drugs. They have antipyretic, analgesic, and apart from acetaminophen, anti-inflammatory activities through the inhibition of prostaglandin synthesis. In addition to these activities, it has been known, but neglected, for over 20 years that antipyretic drugs also have direct and indirect antimicrobial effects (1).

In an era where it is becoming increasingly difficult to find new antimicrobial drugs, it is important to understand these antimicrobial effects and their potential clinical implications. This review summarizes the antimicrobial effects of antipyretic drugs and the underlying mechanisms involved.

DIRECT EFFECTS ON BACTERIA AND FUNGI

(i) Influence on growth and replication. Antipyretics can inhibit and promote the growth or replication of bacteria and fungi. At therapeutic plasma levels, SAL and ASA inhibit the growth of *Campylobacter pylori* (2), *Helicobacter pylori* (3–5), and *Klebsiella pneumoniae* (6), as well as *Epidermophyton floccosum* (7, 8), *Microsporum* spp. (7), and *Trichophyton* spp. (7, 8). Ibuprofen at therapeutic levels inhibits the growth of *Escherichia coli* (9) and, at low pH, also *Staphylococcus aureus*, *Microsporum* spp., and *Trichophyton* spp. (8). Diclofenac inhibits the growth of *E. coli* (10), and flurbiprofen inhibits *Trichophyton* spp. (7).

The MICs of antipyretic drugs from *in vitro* studies are summarized in Table 1. The inhibitory activity of SAL, ibuprofen, diclofenac, and flurbiprofen can occur at concentra-

TABLE 1 MICs of antipyretic drugs

Organism	MIC (mg/ml) (temp [°C], pH of test) (reference) of indicated drug ^a	Acetaminophen (0.01–0.02 [15]) ^b	Salicylic acid (0.15–0.30 [11]) ^b	Ibuprofen (0.01–0.05 [12]) ^b	Diclofenac (0.001–0.002 [13]) ^b	Flurbiprofen (0.009–0.01 [14]) ^b
<i>Acinetobacter baumannii</i>			3.20 (35, NS) ^c (93)	3.20 (35, NS) (93)	1.60 (35, NS) (93)	
<i>Aggregatibacter actinomycetemcomitans</i>				0.25 (37, pH 8.9) (1)		0.25 (37, pH 8.9) (1)
<i>Bacillus</i> spp.	2.50 (35, NS) (82)			0.35 (37, pH 7) (84), 2.50 (35, NS) (82), 1.250 (35, pH 7.4) (19)	0.05 (37, NS) (89), 0.05 (37, NS) (92)	
<i>Burkholderia cepacia</i>			3.20 (35, NS) ^c (93)	>3.2 (35, NS) (93)	0.80 (35, NS) (93)	
<i>Campylobacter pylori</i>			0.13 (37, NS) ^c (2)		0.06 (37, NS) (2)	0.13 (37, pH 8.9) (1)
<i>Eikenella corrodens</i>				0.25 (37, pH 9) (1)		
<i>Enterobacter cloacae</i>	5.00 (35, NS) (82)		3.20 (35, NS) (93)	5.00 (35, NS) (82), >3.20 (35, NS) (93)	1.60 (35, NS) (93)	
<i>Escherichia coli</i>	2.50 (35, NS) (82)		1.00 (37, NS) ^c (109), 1.60 (35, NS) ^c (93), 2.76 (37, NS) (52)	0.02 (NS, NS) (9), 1.00 (37, pH 7.2) (17), 2.50 (35, NS) (82), 3.20 (35, NS) (93)	0.002 (37, NS) (10), 0.05 (37, NS) (92), 0.05 (37, NS) (91), 0.05 (37, NS) (89), 1.60 (35, NS) (93)	
<i>Fusobacterium nucleatum</i>				0.13 (37, pH 8.9) (1)		0.25 (37, pH 8.9) (1)
<i>Helicobacter pylori</i>			0.07 (37, pH 7.5) ^c (5), 0.10 (37, pH 7) (3), 4.00 (37, NS) (83)	0.13 (37, NS) (83)		
<i>Klebsiella</i> spp.			0.05 (37, pH 7.5) (6), 3.20 (35, NS) ^c (93)	>3.20 (35, NS) (93)	0.20 (37, NS) (92), 0.20 (37, NS) (89), 1.60 (35, NS) (93)	
<i>Micrococcus luteus</i>				0.35 (37, pH 7) (84)		
<i>Paracoccus yeii</i>	1.25 (35, NS) (82)			1.25 (35, NS) (82)		
<i>Proteus</i> spp.			1.60 (35, NS) ^c (93)	1.60 (35, NS) (93)	0.20 (35, NS) (93)	
<i>Pseudomonas aeruginosa</i>			1.58 (37, NS) ^c (109), 3.20 (35, NS) ^c (93)	>3.20 (35, NS) (93)	0.05 (37, NS) (92), 0.80 (37, NS) (89), 1.60 (35, NS) (93)	
<i>Salmonella enterica</i> serovar Typhi	2.50 (35, NS) (82)			2.50 (35, NS) (82)		
<i>Salmonella</i> Typhimurium					0.05 (37, NS) (89), 0.05 (37, NS) (92)	
<i>Shigella</i> spp.					0.05 (37, NS) (89), 0.10 (37, NS) (92)	
<i>Staphylococcus aureus</i>	1.25 (35, NS) (82)		>0.16 (35, pH 5) (8)	0.04 (35, pH 5) (8), 0.35 (37, pH 6) (84), 1.25 (35, NS) (82), 6.25 (35, pH 7.4) (19)	0.05 (37, NS) (89), 0.05 (37, NS) (91), 0.05 (37, NS) (92), 10.00 (NS, pH 7) (20)	
<i>Staphylococcus epidermidis</i>			0.69 (37, pH 7.4) (30)	0.35 (37, pH 7) (84)		
<i>Staphylococcus saprophyticus</i>				1.25 (37, pH 7.2) (17)		
<i>Stenotrophomonas maltophilia</i>	3.20 (35, NS) (93)		1.60 (35, NS) ^c (93)	1.60 (35, NS) (93)	0.80 (35, NS) (93)	
<i>Vibrio cholerae</i>					0.05 (37, NS) (89), 0.05 (37, NS) (92)	0.25 (37, pH 8.9) (1)
<i>Wolinnella recta</i>				0.13 (37, pH 8.9) (1)		
<i>Aspergillus brasiliensis</i>				3.10 (35, pH 7.4) (19)		
<i>Aspergillus niger</i>			>0.51 (35, pH 5) (7)			0.26 (35, pH 5) (7)
<i>Candida albicans</i>			>0.26 (35, pH 5) (7), >0.28 (35, pH 5) (8), 1.00 (37, pH 7) ^c (34), 2.65 (37, NS) ^c (109)	0.14 (35, pH 5) (8), 0.50 (37, NS) (16), 1.00 (37, pH 7.2) (17), 2.00 (35, pH 7) (18), 3.10 (35, pH 7.4) (19)	0.05 (37, NS) (16), 10.00 (NS, pH 7) (20)	0.032 (35, pH 5) (7)
<i>Candida glabrata</i>				0.25 (37, NS) (16), 3.00 (35, pH 7) (18)	0.15 (37, pH 7.2) (16)	
<i>Candida krusei</i>				0.25 (37, NS) (16), 1.00 (35, pH 7) (18)	1.00 (37, pH 7.2) (16)	
<i>Epidermophyton floccosum</i>				0.02 (35, pH 5) (8)	0.28 (28, NS) (85)	0.016 (35, pH 5) (7)
<i>Microsporium</i> spp.				0.01 (35, pH 5) (8)		
<i>Mucor</i> spp.			>0.28 (35, pH 5) (8)	0.12 (35, pH 5) (8)		
<i>Penicillium expansum</i>			0.35 (25, pH <5) (110)			0.016 (35, pH 5) (7)
<i>Trichophyton</i> spp.			0.12 (35, pH 5) (8), 0.13 (35, pH 5) (7), 0.14 (25, NS) ^c (111), 1.90 (28, NS) ^c (85)	0.005 (35, pH 5) (8), 0.20 (28, NS) (94)	0.70 (28, NS) (85)	0.008 (35, pH 5) (7)

^aMIC at or below therapeutic plasma levels indicated in bold, NS, not specified.

^bValues in parentheses after the drug name indicate range of therapeutic plasma levels (mg/ml) [reference].

^cAcetylsalicylic acid was used.

tions that are achieved with normal therapeutic doses (11–14). In contrast, the usual therapeutic plasma levels of acetaminophen are lower than the concentration at which inhibition of bacterial growth has been shown (15).

Interestingly, while suprathreshold concentrations of acetaminophen, ibuprofen and diclofenac inhibit the growth of fungi (16–20), one study showed that at therapeutic concentrations, these antipyretics increase the growth of *Candida* spp. (21).

(ii) Motility. SAL reduces the motility of *Burkholderia cepacia*, *E. coli*, *Proteus mirabilis*, *Proteus vulgaris*, *Providencia rettgeri*, *Providencia stuartii*, and *Pseudomonas aeruginosa* (Table 2) (22, 23). However, only in *E. coli* has this effect been shown to occur at therapeutic plasma levels (23). At slightly higher concentrations, SAL reduces flagellin production in *E. coli*, as well as flagellum production in *P. mirabilis* (22). Celecoxib, a nonselective COX-2 inhibitor, reduces flagellar motility in *H. pylori* (24).

(iii) Adherence. Ibuprofen at a very low concentration (0.002 mg/ml) significantly decreases the adhesion of *E. coli* to uroepithelial cells (Table 2). This results from reduced fimbria production, as well as changes in surface hydrophobicity influencing the interaction between bacterial and host cells (9, 25, 26). Ibuprofen also reduces the adherence of *E. coli* to silastic catheters (27). Ibuprofen and diclofenac (tested only above therapeutic plasma levels) inhibit the adherence of *Candida albicans*, *C. glabrata*, and *C. krusei* (16). Diclofenac has higher inhibitory activity against the adherence of *C. albicans* and *C. glabrata*, while ibuprofen has a greater inhibitory effect on the adherence of *C. krusei* (16).

SAL at therapeutic levels reduces fibronectin binding in *S. aureus* and the adherence of *E. coli* to silastic catheters (27, 28). At concentrations slightly above the usual therapeutic plasma level, SAL reduces the production of adhesin in *Staphylococcus epidermidis* and fimbria production in *E. coli* (25, 26, 29, 30). At higher concentrations, it also reduces hemagglutinin production in *E. coli* (26). SAL also prevents the adhesion of *P. aeruginosa* and *S. epidermidis* to human corneal epithelial cells and the adherence of *P. aeruginosa*, *Haemophilus influenzae*, *S. epidermidis*, and *Streptococcus pneumoniae* to contact lenses (31).

(iv) Biofilm production. SAL at therapeutic levels decreases biofilm production by *Candida* spp. (21, 32–34), *E. coli* (25, 26, 35, 36), *P. aeruginosa* (37–39), and *S. epidermidis* (Table 2) (30, 38, 40). Biofilm production by *Salmonella enterica* serovar Typhimurium was also reduced by SAL, but the concentrations tested were not specified (41). One study showed no effect of SAL on biofilm production by *E. coli* (37).

There are conflicting reports on the effects of NSAIDs on biofilm production in fungi. While one study reports that ibuprofen and acetaminophen at therapeutic levels enhance biofilm production in *C. albicans* by inducing the secretion of aspartyl-proteases (21), another study shows a reduction in biofilm production by *Candida* spp. after exposure to ibuprofen and diclofenac at levels above therapeutic concentrations (32). Ibuprofen and diclofenac have a disruptive effect on mature biofilms in *C. albicans*, *C. glabrata*, and *C. krusei* (16).

(v) Other virulence factors. NSAIDs alter the expression of many virulence factors (Table 2). In *E. coli*, SAL modulates the expression of more than 144 genes, and, in *P. aeruginosa*, it modulates the expression of more than 331 genes (37, 39, 42). In *K. pneumoniae*, SAL at very low concentrations reduces the production of the polysaccharide capsule by more than 50% (6, 43, 44). In *P. aeruginosa*, SAL and ASA decrease the production of hemolysin, elastase, protease, and pyocyanin by about 55%, but this was only shown at concentrations above the usual therapeutic levels (37, 39). In *S. aureus*, SAL reduces the production of α -hemolysin (29). In *S. epidermidis*, SAL reduces the production of teichoic acid, polysaccharide capsule, and type 1 antigen (30). In *H. pylori*, ASA and indomethacin reduce urease and vacuolating cytotoxin activities (5, 45). Ibuprofen, at low concentrations, reduces hemolysin production in *E. coli* (9).

(vi) Metabolism. SAL at a concentration above therapeutic plasma levels leads to the downregulation of gluconeogenesis and glycolysis in *S. aureus* (46) and to activation of sugar transport (sorbitol and mannose) in *E. coli* (Table 2) (46). Ibuprofen and

TABLE 2 Direct and indirect antimicrobial effects of antipyretic drugs^a
Organism(s) tested and effect(s) (reference(s)) of indicated drug(s)

Effect	Acetaminophen	Concn (mg/ml)	Salicylic acid	Concn (mg/ml)	Other NSAIDs	Concn (mg/ml)
Motility			Reduction of motility of <i>Burkholderia cepacia</i> (22), <i>Escherichia coli</i> (22, 23), <i>Proteus mirabilis</i> (22), <i>Proteus vulgaris</i> (22), <i>Providencia rettgeri</i> (22), <i>Providencia stuartii</i>	0.69 (22), 0.18 (23)		
			Blocking of flagellin production by <i>Escherichia coli</i> Reduction in flagella production by <i>Proteus mirabilis</i> No effect on motility of <i>Pseudomonas aeruginosa</i>	0.69 (22) 2.76 (22) 0.69 (22)		
Adherence			Reduction of fimbriae production by <i>Escherichia coli</i>	0.35 (25)	Reduction of adhesion of <i>Escherichia coli</i> to uroepithelial cells due to reduced fimbriae production and changes in surface hydrophobicity (ibuprofen)	0.002 (9)
			Reduction of hemagglutinin production by <i>Escherichia coli</i> Reduction of fibronectin binding in <i>Staphylococcus aureus</i> Reduction of adhesion production by <i>Staphylococcus epidermidis</i>	1.38 (26) 0.03 (29) 0.69 (30)	Reduction of adherence of <i>Escherichia coli</i> to silastic catheters (ibuprofen) Reduction of adhesion of <i>Candida albicans</i> , <i>Candida glabrata</i> and <i>Candida krusei</i> (ibuprofen) Reduction of adherence of <i>Pseudomonas aeruginosa</i> , <i>Haemophilus influenzae</i> , <i>Staphylococcus epidermidis</i> , and <i>Streptococcus pneumoniae</i> to contact lenses (diclofenac)	0.39 (27) 0.13 (16) > 0.001 (31)
Biofilm production			Reduction of adherence of <i>Escherichia coli</i> to silastic catheters Reduction of adherence of <i>Pseudomonas aeruginosa</i> , <i>Haemophilus influenzae</i> , <i>Staphylococcus epidermidis</i> , and <i>Streptococcus pneumoniae</i> to contact lenses Reduction of adhesion of <i>Pseudomonas aeruginosa</i> and <i>Staphylococcus epidermidis</i> to human corneal epithelial cells	0.28 (27), 0.14 (28) > 0.01 (31) > 0.01 (31)		
		Increase of biofilm production by <i>Candida</i> spp.	Reduction of biofilm production by <i>Candida</i> spp. Reduction of biofilm production by <i>Escherichia coli</i>	0.2^b (21), 0.14 (32), 0.06^b (33) 0.01 (35)	Increase of biofilm production by <i>Candida</i> spp. (ibuprofen) Reduction of biofilm production by <i>Candida albicans</i> (ibuprofen)	0.02 (21) NS (32)
Other virulence factors			Reduction of biofilm production by <i>Pseudomonas aeruginosa</i> Reduction of biofilm production by <i>Salmonella enterica</i> serovar Typhimurium Reduction of biofilm production by <i>Staphylococcus epidermidis</i>	6 ^b (37), 0.01 (39), 0.14 (38) NS (41) 0.69 (30, 40), 0.14 (38)	Disruption of mature biofilms in <i>Candida albicans</i> , <i>Candida glabrata</i> and <i>Candida krusei</i> (ibuprofen)	NS (16)
			Reduction of polysaccharide capsule production in <i>Klebsiella pneumoniae</i> Reduction of toxin production (hemolysin, elastase, protease, and pyocyanin) in <i>Pseudomonas aeruginosa</i> Reduction of membrane proteins and pathogenicity of <i>Pseudomonas aeruginosa</i> Reduction of urease and vacuolating cytotoxin activity in <i>Helicobacter pylori</i>	0.002 (6), 0.03 (43), 0.35 (44) 1 ^b (37), 1.38 (39) 4.1 (112) 0.69 ^a (5)	Reduction in hemolysin production in <i>Escherichia coli</i> (ibuprofen) Decrease in urease activity in <i>Helicobacter pylori</i> (indomethacin)	0.004 (9) 0.1 (45)

(Continued on following page)

TABLE 2 (Continued)

Organism(s) tested and effect(s) (reference(s) of indicated drug(s))		Concn (mg/ml)	Salicylic acid	Concn (mg/ml)	Other NSAIDs	Concn (mg/ml)
Effect	Acetaminophen	Concn (mg/ml)	Salicylic acid	Concn (mg/ml)	Other NSAIDs	Concn (mg/ml)
Metabolism			Reduction of α -hemolysin production binding in <i>Staphylococcus aureus</i> Reduction of teichoic acid, polysaccharide capsule and type 1 antigen production by <i>Staphylococcus epidermidis</i>	0.03 (29) 0.69 (30)		NS (47, 113) 3 (18)
			Downregulation of gluconeogenesis and glycolysis in <i>Staphylococcus aureus</i> Activation of sugar transport (sorbitol, mannose) in <i>Escherichia coli</i>	0.69 (46) 0.69 (46)	Increase in expression of cytochrome P450 in <i>Bacillus megaterium</i> (ibuprofen/indomethacin) Metabolic alternation and damages of cytoplasmic membrane in <i>Candida</i> spp. (ibuprofen) Inhibition of transition from yeast to hyphae in <i>Candida</i> spp. (ibuprofen)	0.1 (16)
Interaction with immune system	Reduction in transport and release of azithromycin and moxifloxacin by PMNL	0.005 (74)	Reduction in transport and release of azithromycin and moxifloxacin by PMNL	0.005 (74)	Reduction in transport and release of azithromycin and moxifloxacin by PMNL (ibuprofen)	0.005 (74)
			Reduction in uptake of azithromycin by PMNL Increase in phagocytosis of <i>Klebsiella pneumoniae</i> by PMNL	0.005 (74) 0.03 (43), 4 (86)		
Antibiotic susceptibility	Decrease in susceptibility of <i>Serratia marcescens</i> to cefotaxime, kanamycin Induction of β -lactamase activity in <i>Serratia marcescens</i> Increase in susceptibility of <i>Candida</i> spp. to amphotericin B	0.005 (60) 0.005 (60) NS (34)	Decrease in susceptibility of <i>Escherichia coli</i> to ofloxacin Increase in susceptibility of <i>Acinetobacter baumannii</i> to ceftioxone, ciprofloxacin, gentamicin, imipenem Decrease in susceptibility of <i>Burkholderia cepacia</i> to chloramphenicol, ciprofloxacin, trimethoprim Decrease in susceptibility of <i>Campylobacter jejuni</i> to chloramphenicol, ciprofloxacin, erythromycin, rifampin, tetracycline Decrease in susceptibility of <i>Escherichia coli</i> to ampicillin, cephalosporins, chloramphenicol, fluoroquinolones, nalidixic acid, tetracycline Increase in susceptibility of <i>Escherichia coli</i> to aminoglycosides Increase in susceptibility of <i>Helicobacter pylori</i> to amoxicillin, clarithromycin, metronidazole Decrease in susceptibility of <i>Klebsiella pneumoniae</i> to aztreonam, ceftazolin, cefonicid, cefoperazone, ceftizoxime, clindamycin, doxycycline, mezlocillin, norfloxacin, trimethoprim-sulfamethoxazole Increase in susceptibility of <i>Klebsiella pneumoniae</i> amikacin, gentamicin, tobramycin Decrease in susceptibility of <i>Pseudomonas aeruginosa</i> to biapenem, carbenicillin, ceftazopran, ceftiofime, chloramphenicol, ciprofloxacin, gentamicin, imipenem, moxalactam, meropenem, norfloxacin, ofloxacin, panipenem, piperacillin	0.14 (93) 0.35 (65) 1.38 (48) 0.14 (49), 0.10 (50, 51) 0.07 (55), 0.14 (52, 54), 0.69 (53, 87, 88) 0.28 (55) 1.38 (3, 69) 0.35 (44) 0.35 (44, 68) 0.14 (39), 0.55 (56), 4.4 (57)	Increase in susceptibility of <i>Helicobacter pylori</i> to metronidazole and clarithromycin (indomethacin) Decrease in susceptibility of <i>Bacillus pumilus</i> , <i>Escherichia coli</i> , <i>Salmonella Typhimurium</i> , <i>Shigella dysenteriae</i> , <i>Staphylococcus aureus</i> and <i>Vibrio cholerae</i> to streptomycin (diclofenac) Increase in susceptibility of <i>Candida</i> spp. to azoles and amphotericin B (18, 71, 72) (ibuprofen) Reversal of overexpression of efflux pumps in <i>Candida</i> spp. (ibuprofen)	0.04 (45) 0.05 (92) 0.06 (18)

(Continued on following page)

TABLE 2 (Continued)

Organism(s) tested and effect(s) (reference(s)) of indicated drug(s)		Concn (mg/ml)	Other NSAIDs	Concn (mg/ml)
Effect	Acetaminophen	Salicylic acid		
		Increase in susceptibility of <i>Pseudomonas aeruginosa</i> to aztreonam, carbenicillin, cefotaxime, cefpiramide, chloramphenicol, piperacillin		0.55 (56)
		Decrease in susceptibility of <i>Pseudomonas aeruginosa</i> to serovar Typhimurium to ampicillin, cefoperazone, chloramphenicol, ciprofloxacin, nalidixic acid, tetracycline		4.1 (112) 0.69 (58), 0.35 (59)
		Decrease in susceptibility of <i>Serratia marcescens</i> to ampicillin, cefotaxime, cefoxitin, cephaloridine, ciprofloxacin, nalidixic acid, norfloxacin		0.14 (60–62)
		Increase in susceptibility of <i>Serratia marcescens</i> to cephalothin, kanamycin		0.41 (60)
		Decrease in susceptibility of <i>Staphylococcus aureus</i> to ciprofloxacin, norfloxacin, fusidic acid		0.28 (64), 0.69 (63)
		Induction of β -lactamase activity in <i>Serratia marcescens</i>		0.15 (60)
		Increase in susceptibility of <i>Candida</i> spp. to azoles and amphotericin B		0.03 (34)
Mutations		Suppression in the ability of metronidazole to induce mutations to rifampin in <i>Helicobacter pylori</i>		0.10^b (3)
		Increase (70-fold) in frequency of mutations leading to fluoroquinolone resistance in <i>Campylobacter jejuni</i> under selection with ciprofloxacin		0.10 (50)
		Increase in mutations leading to fluoroquinolone resistance in <i>Staphylococcus aureus</i>		0.28 (64, 73), 0.69 (63)
Effects on viruses		Inhibition of hepatitis C virus cell entry (reduction in claudin-1 receptor)		0.55 ^a (75)
		Decrease in hepatitis C virus replication (modulation of inducible nitric oxide synthase and activation of p38 mitogen-activated protein kinase and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2)		0.55 ^b (76, 77)
		Decrease of influenza virus replication (inhibition of nuclear factor-kappa B)		0.14^b (78)
		Decrease of flavivirus replication (activation of p38 mitogen-activated protein kinase)		0.14 (79)

^aConcentrations at or below therapeutic plasma levels are indicated in bold. NS, not specified. PMNL, polymorphonuclear leukocytes.

^bAcetylsalicylic acid was used.

indomethacin induce cytochrome P450 (CYP) production in *Bacillus megaterium*, which renders the bacteria considerably more sensitive to oxidant insults (47). Ibuprofen at high concentrations induces metabolic alternation and also damages the cytoplasmic membrane in *Candida* spp. (18). It also inhibits the transition from yeast to hyphae and, therefore, germ tube formation in *Candida* spp. (16).

INDIRECT EFFECTS ON BACTERIA AND FUNGI

Interaction with antimicrobials. SAL increases the antimicrobial susceptibility of many pathogens. Less commonly, it leads to decreased susceptibility, mainly to aminoglycosides but also to β -lactams and fluoroquinolones (Table 2) (3, 39, 44, 48–68). When *H. pylori* is exposed to ASA and other COX inhibitors, its susceptibility to amoxicillin, clarithromycin, and metronidazole increases (3, 45, 69, 70). In *Serratia marcescens*, ASA, SAL, and acetaminophen at therapeutic plasma levels induce β -lactamase activity (60). Acetaminophen at low levels also decreases the susceptibility of *S. marcescens* to cefotaxime and kanamycin (60). In *Candida* spp., ibuprofen or ASA in combination with azoles and amphotericin B leads to synergistic effects (18, 34, 71, 72). The MICs of *Candida* spp. to fluconazole decrease up to 128-fold in the presence of ibuprofen (18). By reversing the overexpression of efflux pumps, ibuprofen can diminish *Candida* resistance (72).

The main mechanism underlying changes in susceptibility is a change in the permeability of the outer membrane porin protein (OMP) to antibiotics. This is mainly through decreases or increases of OMPs or efflux pumps.

Antipyretics may also alter susceptibility to antibiotics by inducing mutations in bacterial genes. SAL at therapeutic levels suppresses the ability of metronidazole to induce mutations to rifampin in *H. pylori* (3). In contrast, in *Campylobacter jejuni*, under pressure from ciprofloxacin, SAL increases the frequency of mutations, leading to as much as a 70-fold increase in fluoroquinolone resistance (50). SAL also increases mutations leading to fluoroquinolone resistance in *S. aureus* (63, 64, 73).

Acetaminophen, SAL, and ibuprofen at very low concentrations reduce the transport and release of azithromycin and moxifloxacin by polymorphonuclear leukocytes (PMNL) (Table 2) (74). SAL also reduces the uptake of azithromycin by PMNL (74).

EFFECTS ON VIRUSES

ASA/SAL inhibit the cell entry and replication of hepatitis C virus (75–77), as well as the replication of flavivirus and influenza virus (78, 79). The inhibition of replication mostly occurs at therapeutic levels (78, 79). One of the underlying mechanisms is inhibition of the transcription factor nuclear factor-kappa B, which is critical for the inducible expression of multiple cellular and viral genes involved in inflammation, including interleukin-1 (IL-1), IL-6, and adhesion molecules (78, 80). Another mechanism is the activation of p38 mitogen-activated protein kinase and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 (76, 77, 79).

DISCUSSION

As antipyretics are commonly coadministered with antimicrobial therapy, it is important to understand the interactions between these two classes of drugs. Antipyretics primarily act by inhibiting prostaglandin synthesis. Fungi (unlike bacteria and viruses) produce prostaglandins, and although their exact function is uncertain, it is thought that they influence virulence, in particular controlling the yeast-to-hypha transition and biofilm production (32, 34, 81). Aside from prostaglandin inhibition, as detailed in this review, other mechanisms by which antipyretic drugs influence pathogens include inhibiting virus replication (75–79), inhibiting or promoting bacterial and fungal growth (1–3, 5–9, 16–21, 34, 45, 52, 82–85), altering the expression of virulence factors (5, 6, 9, 29, 30, 37, 39, 43–45), changing the surface hydrophobicity of microbes (9), influencing biofilm production (16, 21, 30, 32, 33, 35, 37–41), affecting motility (22, 23), adherence (9, 16, 25–31), and metabolism (16, 18, 46), interacting with the transport and release of antibiotics by PMNL (43, 74, 86), modifying the susceptibility of microbes to antimicrobial therapy (3, 18, 34, 39, 44, 45, 48–65, 68, 69, 72, 87, 88), and inducing or reducing the frequency of mutations leading to antimicrobial resistance (3, 50, 63, 64, 73).

SAL mostly inhibits the growth of Gram-negative bacteria and fungi, while ibuprofen and diclofenac also inhibit the growth of Gram-positive bacteria, though this may simply reflect the particular bacteria that were chosen for testing in different studies (2, 3, 5–8, 51, 52, 60, 84, 89–92). In considering the clinical relevance of the antimicrobial effects of antipyretics, it is important to understand that the reported MICs of antipyretic drugs vary, sometimes considerably, according to the culture medium, incubation temperature, and pH used. Inhibition of growth is greater at pHs lower than 7 (7, 8, 19, 84). The use of different temperatures and pH conditions in the studies summarized in Table 1 limits comparison. In addition, the antipyretic concentrations also vary between studies, and it is possible that lower concentrations, had they been tested, might also inhibit growth. While some studies use ASA for the determination of MICs, others use SAL, which is the active *in vivo* metabolite of ASA. One study, which compared the MICs of the two forms, showed a twofold difference, suggesting that results obtained using these drugs are not directly comparable (60). Since ASA is rapidly degraded to SAL *in vivo*, the data for SAL was used whenever possible in this review. Interestingly, a recent study showed that NSAIDs are substrates of efflux pumps in Gram-negative bacteria. When the pumps are inhibited by an additional drug, the MICs to NSAIDs decrease significantly (93). This combination therapy, as well as changes in the structure of antipyretics, might increase the antimicrobial activities of antipyretics. Further studies are necessary to determine the full range of MICs of antipyretic drugs.

Although many of the MICs for antipyretic drugs are above the therapeutic plasma levels normally attained, higher drug concentrations might be reached in urine, synovia, or with topical therapy. Antipyretic drugs in those situations might reach levels where they inhibit microbial growth or influence microbes by some of the other mechanisms described. Topical ibuprofen, for example, is more effective in suppressing the growth of *Trichophyton* than topical clotrimazole (94). Another example is that two thirds of women with uncomplicated urinary tract infections (80% with *E. coli*) treated with ibuprofen recover without antibiotics (95). Although this finding is considered to result from the anti-inflammatory effects of ibuprofen, it might also be attributable to the antimicrobial effects of ibuprofen, which include blocking of adherence to uroepithelial cells, reduced motility, and reduced toxin and biofilm production, as well as inhibition of growth (9, 25, 26). Diclofenac and other NSAIDs inhibit bacterial DNA synthesis (10, 91) in *E. coli*; this was shown to be through the inhibition of a DNA polymerase (96).

Of further particular relevance for clinical practice is the effect of NSAIDs on the antibiotic susceptibility of pathogens. Changes in susceptibility mostly result from a change in direct antimicrobial penetration through cell membranes of bacteria or from an increase or decrease in efflux through the membranes (3, 39, 44, 48–68). However, decreased susceptibility can also result from induced β -lactamase activity (60). By understanding these mechanisms, these synergistic effects can be exploited in the treatment of infectious diseases and potential compromising effects on antimicrobial efficacy can be avoided. Notably, SAL at therapeutic levels can increase or decrease the frequency of resistance mutations in bacteria under antibiotic pressure, and ibuprofen reverses overexpression of efflux pumps and can therefore reverse resistance in *Candida* spp. (3, 50, 63, 64, 72, 73). Furthermore, ibuprofen also increases the susceptibility of *Candida* spp. to azoles or amphotericin B. Both mechanisms are promising for treatment of resistant fungal infections (18, 34, 71, 72). Several NSAIDs are metabolized through CYP enzymes. CYPs have also been identified in bacteria, with the highest number in mycobacteria (97). The one study reporting the effect of antipyretics on bacterial CYPs found that an induction of CYPs renders bacteria more sensitive to oxidant insults (47).

More evidence for the potential antimicrobial effect of antipyretics can be drawn from animal studies. In mice, ASA and ibuprofen enhance the effect of pyrazinamide during the initial phase of tuberculosis treatment and diclofenac protects mice from dying from *Salmonella* infection (89, 98). In cows, higher peak levels of ceftizoxime can

be detected in plasma after coadministration with acetaminophen (99). In rabbits with *S. aureus* endocarditis, ASA reduces vegetation bacterial density, hematogenous bacterial dissemination, and the frequency of embolic events (100). While treatment with NSAIDs improves survival in sepsis in animal models (101–103), this was not the case in one study in humans (104).

It is difficult to discern which of the effects outlined in this paper are the most clinically relevant. Good evidence exists for SAL-induced induction of phenotypic resistance in Gram-negative bacteria through permeability changes of the outer membrane (downregulation of OMPs, upregulation of efflux pumps, and increase in membrane potential) (36, 48, 50, 53, 56–58, 60, 87, 88, 105–107). However, it is unclear whether these effects, observed *in vitro*, compromise the efficacy of antimicrobial therapy *in vivo* or if they can be used beneficially. There is also the possibility of SAL leading to the selection of resistant bacteria by these mechanisms. Further studies are necessary to determine whether concurrent use of SAL necessitates a change in antibiotic dose.

Good evidence also exists for the reduction of biofilm formation and bacterial adherence by SAL in *Candida* spp., *E. coli*, *Salmonella*, *S. aureus*, *S. epidermidis*, and *P. aeruginosa* (21, 25–33, 35, 37–41) and by ibuprofen in *Candida* spp. and *E. coli* (9, 16, 28). This could be helpful in the treatment of infections in the presence of foreign material, especially intravenous or urine catheters.

Interpretation of the findings of the studies identified in this systematic review is limited by the heterogeneity of the studies, including the wide variation in the concentrations of antipyretics used, the particular pathogens and microbial factors chosen to test, and the culture conditions used in the different studies. The potential detrimental effects of antipyretics on the immune response to infection have been discussed previously (108). Our review highlights that antipyretic drugs also influence the response to antimicrobial therapy. In general, NSAIDs have broad-spectrum antimicrobial activity, although apart from SAL/ASA, inhibition of pathogen growth mostly occurs at levels above therapeutic plasma concentrations. However, antipyretics also have potent activity in reducing adherence, biofilm production, and other virulence factors, as well as the ability to both increase and decrease antibiotic susceptibility. Targeting virulence factors and reducing resistance provides a novel strategy to enhance antimicrobial therapy. Antipyretics could be useful in the management of biofilm-associated infections, as adjuvant therapy in viral, bacterial, and fungal infections, or in reducing antimicrobial resistance. Changes in the structure of antipyretics might increase their antimicrobial activities, and further research might lead to potent antimicrobial agents.

ACKNOWLEDGMENTS

P.Z. drafted the initial manuscript and approved the final manuscript as submitted. N.C. critically reviewed and revised the manuscript and approved the final manuscript as submitted.

P.Z. was supported by grants from the Bangerter-Rhyner Foundation, the Cloetta Foundation, and the Ettore-Rossi Foundation.

The authors declare that they have no competing interests and no conflict of interest.

REFERENCES

1. Hersh EV, Hammond BF, Fleury AA. 1991. Antimicrobial activity of flurbiprofen and ibuprofen *in vitro* against six common periodontal pathogens. *J Clin Dent* 3:1–5.
2. Caselli M, Pazzi P, LaCorte R, Aleotti A, Trevisani L, Stabellini G. 1989. Campylobacter-like organisms, nonsteroidal anti-inflammatory drugs and gastric lesions in patients with rheumatoid arthritis. *Digestion* 44:101–104.
3. Wang WH, Wong WM, Dailidienė D, Berg DE, Gu Q, Lai KC, Lam SK, Wong BC. 2003. Aspirin inhibits the growth of *Helicobacter pylori* and enhances its susceptibility to antimicrobial agents. *Gut* 52:490–495. <https://doi.org/10.1136/gut.52.4.490>.
4. Ma D, Cook DN, Alberti M, Pon NG, Nikaido H, Hearst JE. 1995. Genes *acrA* and *acrB* encode a stress-induced efflux system of *Escherichia coli*. *Mol Microbiol* 16:45–55. <https://doi.org/10.1111/j.1365-2958.1995.tb02390.x>.
5. Ma H-X, Wang W-H, Hu F-L, Li J. 2006. Effect of aspirin and celecoxib on *Helicobacter pylori* *in vitro*. *Shijie Huaren Xiaohua Zazhi* 14:2747–2752.
6. Domenico P, Schwartz S, Cunha BA. 1989. Reduction of capsular poly-

- saccharide production in *Klebsiella pneumoniae* by sodium salicylate. *Infect Immun* 57:3778–3782.
7. Chowdhury B, Adak M, Bose SK. 2003. Flurbiprofen, a unique non-steroidal anti-inflammatory drug with antimicrobial activity against *Trichophyton*, *Microsporum* and *Epidermophyton* species. *Lett Appl Microbiol* 37:158–161. <https://doi.org/10.1046/j.1472-765X.2003.01370.x>.
 8. Sanyal AK, Roy D, Chowdhury B, Banerjee AB. 1993. Ibuprofen, a unique anti-inflammatory compound with antifungal activity against dermatophytes. *Lett Appl Microbiol* 17:109–111. <https://doi.org/10.1111/j.1472-765X.1993.tb01436.x>.
 9. Drago L, De Vecchi E, Nicola L, Valli M, Gismondo MR. 2002. Effects of subinhibitory concentrations of ibuprofen isobuthanolammonium on virulence factors of uropathogenic *Escherichia coli*. *J Chemother* 14:314–315. <https://doi.org/10.1179/joc.2002.14.3.314>.
 10. Mazumdar K, Dutta NK, Dastidar SG, Motohashi N, Shirataki Y. 2006. Diclofenac in the management of *E. coli* urinary tract infections. *In Vivo* 20:613–619.
 11. Dargan PI, Wallace CI, Jones AL. 2002. An evidence based flowchart to guide the management of acute salicylate (aspirin) overdose. *Emerg Med J* 19:206–209. <https://doi.org/10.1136/emj.19.3.206>.
 12. Hall AH, Smolinske SC, Conrad FL, Wruk KM, Kulig KW, Dwelle TL, Rumack BH. 1986. Ibuprofen overdose: 126 cases. *Ann Emerg Med* 15:1308–1313. [https://doi.org/10.1016/S0196-0644\(86\)80617-5](https://doi.org/10.1016/S0196-0644(86)80617-5).
 13. Scallion R, Moore KA. 2009. Effects of food intake on the pharmacokinetics of diclofenac potassium soft gelatin capsules: a single-dose, randomized, two-way crossover study. *Clin Ther* 31:2233–2241. <https://doi.org/10.1016/j.clinthera.2009.10.001>.
 14. Daravath B, Tadikonda RR, Vemula SK. 2015. Formulation and pharmacokinetics of gelucire solid dispersions of flurbiprofen. *Drug Dev Ind Pharm* 41:1254–1262. <https://doi.org/10.3109/03639045.2014.940963>.
 15. McGill MR, Jaeschke H. 2013. Metabolism and disposition of acetaminophen: recent advances in relation to hepatotoxicity and diagnosis. *Pharm Res* 30:2174–2187. <https://doi.org/10.1007/s11095-013-1007-6>.
 16. Ashraf A, Yousri F, Taha N, El-Waly OA, Ramadan AE-K, Ismail E, Hamada R, Khalaf M, Refaei M, Ali S, Madyan A, El-Baky RMA. 2015. Effect of some non steroidal anti-inflammatory drugs on growth, adherence and mature biofilms of *Candida* spp. *Am J Microbiol Res* 3:1–7. <https://doi.org/10.12691/ajmr-3-1-1>.
 17. Cederlund H, Mardh PA. 1993. Antimicrobial activities of N-acetylcysteine and some non-steroidal anti-inflammatory drugs. *J Antimicrob Chemother* 32:903–904. <https://doi.org/10.1093/jac/32.6.903>.
 18. Pina-Vaz C, Sansonetty F, Rodrigues AG, Martinez-De-Oliveira J, Fonseca AF, Mardh PA. 2000. Antifungal activity of ibuprofen alone and in combination with fluconazole against *Candida* species. *J Med Microbiol* 49:831–840. <https://doi.org/10.1099/0022-1317-49-9-831>.
 19. Obad J, Suskovic J, Kos B. 2015. Antimicrobial activity of ibuprofen: new perspectives on an “old” non-antibiotic drug. *Eur J Pharm Sci* 71:93–98. <https://doi.org/10.1016/j.ejps.2015.02.011>.
 20. Kruszewska H, Zareba T, Tyski S. 2002. Search of antimicrobial activity of selected non-antibiotic drugs. *Acta Polon Pharm* 59:436–439.
 21. Carvalho AP, Gursky LC, Rosa RT, Rymovicz AU, Campelo PM, Gregio AM, Koga-Ito CY, Samaranyake LP, Rosa EA. 2010. Non-steroidal anti-inflammatory drugs may modulate the protease activity of *Candida albicans*. *Microb Pathog* 49:315–322. <https://doi.org/10.1016/j.micpath.2010.07.007>.
 22. Kunin CM, Hua TH, Bakaletz LO. 1995. Effect of salicylate on expression of flagella by *Escherichia coli* and *Proteus*, *Providencia*, and *Pseudomonas* spp. *Infect Immun* 63:1796–1799.
 23. Repaske DR, Adler J. 1981. Change in intracellular pH of *Escherichia coli* mediates the chemotactic response to certain attractants and repellents. *J Bacteriol* 145:1196–1208.
 24. Wang J, Wang WH, Li J, Liu FX. 2010. Celecoxib inhibits *Helicobacter pylori* colonization-related factors. *World J Gastroenterol* 16:846–853. <https://doi.org/10.3748/wjg.v16.i7.846>.
 25. Kunin CM, Hua TH, Guerrant RL, Bakaletz LO. 1994. Effect of salicylate, bismuth, osmolytes, and tetracycline resistance on expression of fimbriae by *Escherichia coli*. *Infect Immun* 62:2178–2186.
 26. Kang G, Balasubramanian KA, Koshi AR, Mathan MM, Mathan VI. 1998. Salicylate inhibits fimbriae mediated HEP-2 cell adherence of and haemagglutination by enteroaggregative *Escherichia coli*. *FEMS Microbiol Lett* 166:257–265. <https://doi.org/10.1111/j.1574-6968.1998.tb13899.x>.
 27. Farber BF, Wolff AG. 1992. The use of nonsteroidal anti-inflammatory drugs to prevent adherence of *Staphylococcus epidermidis* to medical polymers. *J Infect Dis* 166:861–865. <https://doi.org/10.1093/infdis/166.4.861>.
 28. Farber BF, Wolff AG. 1993. The use of salicylic acid to prevent the adherence of *Escherichia coli* to silastic catheters. *J Urol* 149:667–670.
 29. Kupferwasser LI, Yeaman MR, Nast CC, Kupferwasser D, Xiong YQ, Palma M, Cheung AL, Bayer AS. 2003. Salicylic acid attenuates virulence in endovascular infections by targeting global regulatory pathways in *Staphylococcus aureus*. *J Clin Invest* 112:222–233. <https://doi.org/10.1172/JCI200316876>.
 30. Muller E, Al-Attar J, Wolff AG, Farber BF. 1998. Mechanism of salicylate-mediated inhibition of biofilm in *Staphylococcus epidermidis*. *J Infect Dis* 177:501–503. <https://doi.org/10.1086/517386>.
 31. Bandara BM, Sankaridurg PR, Willcox MD. 2004. Non-steroidal anti-inflammatory agents decrease bacterial colonisation of contact lenses and prevent adhesion to human corneal epithelial cells. *Curr Eye Res* 29:245–251. <https://doi.org/10.1080/02713680490516729>.
 32. Alem MA, Douglas LJ. 2004. Effects of aspirin and other nonsteroidal anti-inflammatory drugs on biofilms and planktonic cells of *Candida albicans*. *Antimicrob Agents Chemother* 48:41–47. <https://doi.org/10.1128/AAC.48.1.41-47.2004>.
 33. Stepanovic S, Vukovic D, Jestic M, Ranin L. 2004. Influence of acetylsalicylic acid (aspirin) on biofilm production by *Candida* species. *J Chemother* 16:134–138. <https://doi.org/10.1179/joc.2004.16.2.134>.
 34. Zhou Y, Wang G, Li Y, Liu Y, Song Y, Zheng W, Zhang N, Hu X, Yan S, Jia J. 2012. In vitro interactions between aspirin and amphoterin B against planktonic cells and biofilm cells of *Candida albicans* and *C. parapsilosis*. *Antimicrob Agents Chemother* 56:3250–3260. <https://doi.org/10.1128/AAC.06082-11>.
 35. Vila J, Soto SM. 2012. Salicylate increases the expression of *marA* and reduces in vitro biofilm formation in uropathogenic *Escherichia coli* by decreasing type 1 fimbriae expression. *Virulence* 3:280–285. <https://doi.org/10.4161/viru.19205>.
 36. Chubiz LM, Rao CV. 2011. Role of the *mar-sox-rob* regulon in regulating outer membrane porin expression. *J Bacteriol* 193:2252–2260. <https://doi.org/10.1128/JB.01382-10>.
 37. El-Mowafy SA, Abd El Galil KH, El-Messery SM, Shaaban MI. 2014. Aspirin is an efficient inhibitor of quorum sensing, virulence and toxins in *Pseudomonas aeruginosa*. *Microb Pathog* 74:25–32. <https://doi.org/10.1016/j.micpath.2014.07.008>.
 38. Farber BF, Hsieh HC, Donnenfeld ED, Perry HD, Epstein A, Wolff A. 1995. A novel antibiofilm technology for contact lens solutions. *Ophthalmology* 102:831–836. [https://doi.org/10.1016/S0161-6420\(95\)30949-9](https://doi.org/10.1016/S0161-6420(95)30949-9).
 39. Prithiviraj B, Bais HP, Weir T, Suresh B, Najjarro EH, Dayakar BV, Schweizer HP, Vivanco JM. 2005. Down regulation of virulence factors of *Pseudomonas aeruginosa* by salicylic acid attenuates its virulence on *Arabidopsis thaliana* and *Caenorhabditis elegans*. *Infect Immun* 73:5319–5328. <https://doi.org/10.1128/IAI.73.9.5319-5328.2005>.
 40. Teichberg S, Farber BF, Wolff AG, Roberts B. 1993. Salicylic acid decreases extracellular biofilm production by *Staphylococcus epidermidis*: electron microscopic analysis. *J Infect Dis* 167:1501–1503. <https://doi.org/10.1093/infdis/167.6.1501>.
 41. Rosenberg LE, Carbone AL, Romling U, Uhrich KE, Chikindas ML. 2008. Salicylic acid-based poly(anhydride esters) for control of biofilm formation in *Salmonella enterica* serovar Typhimurium. *Lett Appl Microbiol* 46:593–599. <https://doi.org/10.1111/j.1472-765X.2008.02356.x>.
 42. Barbosa TM, Levy SB. 2000. Differential expression of over 60 chromosomal genes in *Escherichia coli* by constitutive expression of *MarA*. *J Bacteriol* 182:3467–3474. <https://doi.org/10.1128/JB.182.12.3467-3474.2000>.
 43. Salo RJ, Domenico P, Tomas JM, Straus DC, Merino S, Benedi VJ, Cunha BA. 1995. Salicylate-enhanced exposure of *Klebsiella pneumoniae* subcapsular components. *Infection* 23:371–377. <https://doi.org/10.1007/BF01713568>.
 44. Domenico P, Hopkins T, Cunha BA. 1990. The effect of sodium salicylate on antibiotic susceptibility and synergy in *Klebsiella pneumoniae*. *J Antimicrob Chemother* 26:343–351. <https://doi.org/10.1093/jac/26.3.343>.
 45. Gu Q, Xia HH, Wang WH, Wang JD, Wong WM, Chan AO, Yuen MF, Lam SK, Cheung HK, Liu XG, Wong BC. 2004. Effect of cyclo-oxygenase inhibitors on *Helicobacter pylori* susceptibility to metronidazole and clarithromycin. *Aliment Pharmacol Ther* 20:675–681. <https://doi.org/10.1111/j.1365-2036.2004.02168.x>.

46. Pomposiello PJ, Bennik MH, Demple B. 2001. Genome-wide transcriptional profiling of the *Escherichia coli* responses to superoxide stress and sodium salicylate. *J Bacteriol* 183:3890–3902. <https://doi.org/10.1128/JB.183.13.3890-3902.2001>.
47. English NT, Rankin LC. 1997. Antioxidant-mediated attenuation of the induction of cytochrome P450BM-3 (CYP102) by ibuprofen in *Bacillus megaterium* ATCC 14581. *Biochem Pharmacol* 54:443–450. [https://doi.org/10.1016/S0006-2952\(97\)00054-3](https://doi.org/10.1016/S0006-2952(97)00054-3).
48. Burns JL, Clark DK. 1992. Salicylate-inducible antibiotic resistance in *Pseudomonas cepacia* associated with absence of a pore-forming outer membrane protein. *Antimicrob Agents Chemother* 36:2280–2285. <https://doi.org/10.1128/AAC.36.10.2280>.
49. Randall LP, Ridley AM, Cooles SW, Sharma M, Sayers AR, Pumbwe L, Newell DG, Piddock LJ, Woodward MJ. 2003. Prevalence of multiple antibiotic resistance in 443 *Campylobacter* spp. isolated from humans and animals. *J Antimicrob Chemother* 52:507–510. <https://doi.org/10.1093/jac/dkg379>.
50. Shen Z, Pu XY, Zhang Q. 2011. Salicylate functions as an efflux pump inducer and promotes the emergence of fluoroquinolone-resistant *Campylobacter jejuni* mutants. *Appl Environ Microbiol* 77:7128–7133. <https://doi.org/10.1128/AEM.00763-11>.
51. Hannula M, Hanninen ML. 2008. Effect of putative efflux pump inhibitors and inducers on the antimicrobial susceptibility of *Campylobacter jejuni* and *Campylobacter coli*. *J Med Microbiol* 57:851–855. <https://doi.org/10.1099/jmm.0.47823-0>.
52. Rosner JL. 1985. Nonheritable resistance to chloramphenicol and other antibiotics induced by salicylates and other chemotactic repellents in *Escherichia coli* K-12. *Proc Natl Acad Sci U S A* 82:8771–8774. <https://doi.org/10.1073/pnas.82.24.8771>.
53. Cohen SP, Levy SB, Foulds J, Rosner JL. 1993. Salicylate induction of antibiotic resistance in *Escherichia coli*: activation of the *mar* operon and a *mar*-independent pathway. *J Bacteriol* 175:7856–7862. <https://doi.org/10.1128/jb.175.24.7856-7862.1993>.
54. Foulds J, Murray DM, Chai T, Rosner JL. 1989. Decreased permeation of cephalosporins through the outer membrane of *Escherichia coli* grown in salicylates. *Antimicrob Agents Chemother* 33:412–417. <https://doi.org/10.1128/AAC.33.4.412>.
55. Aumercier M, Murray DM, Rosner JL. 1990. Potentiation of susceptibility to aminoglycosides by salicylate in *Escherichia coli*. *Antimicrob Agents Chemother* 34:786–791. <https://doi.org/10.1128/AAC.34.5.786>.
56. Sumita Y, Fukasawa M. 1993. Transient carbapenem resistance induced by salicylate in *Pseudomonas aeruginosa* associated with suppression of outer membrane protein D2 synthesis. *Antimicrob Agents Chemother* 37:2743–2746. <https://doi.org/10.1128/AAC.37.12.2743>.
57. Masuda N, Sakagawa E, Ohya S. 1995. Outer membrane proteins responsible for multiple drug resistance in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 39:645–649. <https://doi.org/10.1128/AAC.39.3.645>.
58. Hartog E, Menashe O, Kler E, Yaron S. 2010. Salicylate reduces the antimicrobial activity of ciprofloxacin against extracellular *Salmonella enterica* serovar Typhimurium, but not against *Salmonella* in macrophages. *J Antimicrob Chemother* 65:888–896. <https://doi.org/10.1093/jac/dkq077>.
59. Randall LP, Woodward MJ. 2001. Multiple antibiotic resistance (*mar*) locus in *Salmonella enterica* serovar Typhimurium DT104. *Appl Environ Microbiol* 67:1190–1197. <https://doi.org/10.1128/AEM.67.3.1190-1197.2001>.
60. Puig M, Palomar J, Loren JG, Vinas M. 1995. Modification by analgesics of the susceptibility to antibiotics in *Serratia marcescens*. *New Microbiol* 18:385–390.
61. Berlanga M, Vinas M. 2000. Salicylate induction of phenotypic resistance to quinolones in *Serratia marcescens*. *J Antimicrob Chemother* 46:279–282. <https://doi.org/10.1093/jac/46.2.279>.
62. Begic S, Worobec EA. 2007. Fluoroquinolone resistance of *Serratia marcescens*: sucrose, salicylate, temperature, and pH induction of phenotypic resistance. *Can J Microbiol* 53:1239–1245. <https://doi.org/10.1139/W07-097>.
63. Gustafson JE, Candelaria PV, Fisher SA, Goodridge JP, Lichocik TM, McWilliams TM, Price CT, O'Brien FG, Grubb WB. 1999. Growth in the presence of salicylate increases fluoroquinolone resistance in *Staphylococcus aureus*. *Antimicrob Agents Chemother* 43:990–992.
64. Price CT, O'Brien FG, Shelton BP, Warmingtton JR, Grubb WB, Gustafson JE. 1999. Effects of salicylate and related compounds on fusidic acid MICs in *Staphylococcus aureus*. *J Antimicrob Chemother* 44:57–64. <https://doi.org/10.1093/jac/44.1.57>.
65. Bazyleu A, Kumar A. 2014. Incubation temperature, osmolarity, and salicylate affect the expression of resistance-nodulation-division efflux pumps and outer membrane porins in *Acinetobacter baumannii* ATCC19606T. *FEMS Microbiol Lett* 357:136–143. <https://doi.org/10.1111/1574-6968.12530>.
66. Cohen SP, McMurry LM, Levy SB. 1988. *marA* locus causes decreased expression of *OmpF* porin in multiple-antibiotic-resistant (*Mar*) mutants of *Escherichia coli*. *J Bacteriol* 170:5416–5422. <https://doi.org/10.1128/jb.170.12.5416-5422.1988>.
67. Cohen SP, McMurry LM, Hooper DC, Wolfson JS, Levy SB. 1989. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (*Mar*) *Escherichia coli* selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to *OmpF* reduction. *Antimicrob Agents Chemother* 33:1318–1325. <https://doi.org/10.1128/AAC.33.8.1318>.
68. Domenico P, Hopkins T, Schoch PE, Cunha BA. 1990. Potentiation of aminoglycoside inhibition and reduction of capsular polysaccharide production in *Klebsiella pneumoniae* by sodium salicylate. *J Antimicrob Chemother* 25:903–914. <https://doi.org/10.1093/jac/25.6.903>.
69. Zhang XP, Wang WH, Tian Y, Gao W, Li J. 2009. Aspirin increases susceptibility of *Helicobacter pylori* to metronidazole by augmenting endocellular concentrations of antimicrobials. *World J Gastroenterol* 15:919–926. <https://doi.org/10.3748/wjg.15.919>.
70. Wang WH, Hu FL, Cy Wong B, Berg DE, Lam S-K. 2002. Inhibitory effects of aspirin and indometacin on the growth of *Helicobacter pylori* in vitro. *Chin J Dig Dis* 3:172–177. <https://doi.org/10.1046/j.1443-9573.2002.00098.x>.
71. Tariq VN, Scott EM, McCain NE. 1995. Use of decimal assay for additivity to demonstrate synergy in pair combinations of econazole, nikkomycin Z, and ibuprofen against *Candida albicans* in vitro. *Antimicrob Agents Chemother* 39:2615–2619. <https://doi.org/10.1128/AAC.39.12.2615>.
72. Pina-Vaz C, Rodrigues AG, Costa-de-Oliveira S, Ricardo E, Mardh PA. 2005. Potent synergic effect between ibuprofen and azoles on *Candida* resulting from blockade of efflux pumps as determined by FUN-1 staining and flow cytometry. *J Antimicrob Chemother* 56:678–685. <https://doi.org/10.1093/jac/dki264>.
73. Price CT, Gustafson JE. 2001. Increases in the mutation frequency at which fusidic acid-resistant *Staphylococcus aureus* arise with salicylate. *J Med Microbiol* 50:104–106. <https://doi.org/10.1099/0022-1317-50-1-104>.
74. Mandell GL, Coleman EJ. 2002. Effect of antipyretic agents on uptake, transport, and release of antimicrobial agents by human polymorphonuclear leukocytes. *J Infect Dis* 185:1314–1319. <https://doi.org/10.1086/340135>.
75. Yin P, Zhang L. 2016. Aspirin inhibits hepatitis C virus entry by down-regulating claudin-1. *J Viral Hepat* 23:62–64. <https://doi.org/10.1111/jvh.12446>.
76. Rios-Ibarra CP, Lozano-Sepulveda S, Munoz-Espinosa L, Rincon-Sanchez AR, Cordova-Fletes C, Rivas-Estilla AM. 2014. Downregulation of inducible nitric oxide synthase (iNOS) expression is implicated in the antiviral activity of acetylsalicylic acid in HCV-expressing cells. *Arch Virol* 159:3321–3328. <https://doi.org/10.1007/s00705-014-2201-5>.
77. Trujillo-Murillo K, Rincon-Sanchez AR, Martinez-Rodriguez H, Bosques-Padilla F, Ramos-Jimenez J, Barrera-Saldana HA, Rojkind M, Rivas-Estilla AM. 2008. Acetylsalicylic acid inhibits hepatitis C virus RNA and protein expression through cyclooxygenase 2 signaling pathways. *Hepatology* 47:1462–1472. <https://doi.org/10.1002/hep.22215>.
78. Mazur I, Wurzer WJ, Ehrhardt C, Pleschka S, Puthavathana P, Silberzahn T, Wolff T, Planz O, Ludwig S. 2007. Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF- κ B-inhibiting activity. *Cell Microbiol* 9:1683–1694. <https://doi.org/10.1111/j.1462-5822.2007.00902.x>.
79. Liao CL, Lin YL, Wu BC, Tsao CH, Wang MC, Liu CI, Huang YL, Chen JH, Wang JP, Chen LK. 2001. Salicylates inhibit flavivirus replication independently of blocking nuclear factor kappa B activation. *J Virol* 75:7828–7839. <https://doi.org/10.1128/JVI.75.17.7828-7839.2001>.
80. Kopp E, Ghosh S. 1994. Inhibition of NF- κ B by sodium salicylate and aspirin. *Science* 265:956–959. <https://doi.org/10.1126/science.8052854>.
81. Erb-Downward JR, Noverr MC. 2007. Characterization of prostaglandin E2 production by *Candida albicans*. *Infect Immun* 75:3498–3505. <https://doi.org/10.1128/IAI.00232-07>.

82. Al-Janabi AA. 2010. In vitro antibacterial activity of ibuprofen and acetaminophen. *J Global Infect Dis* 2:105–108. <https://doi.org/10.4103/0974-777X.62880>.
83. Shirin H, Moss SF, Kancherla S, Kancherla K, Holt PR, Weinstein IB, Sordillo EM. 2006. Non-steroidal anti-inflammatory drugs have bacteriostatic and bactericidal activity against *Helicobacter pylori*. *J Gastroenterol Hepatol* 21:1388–1393. <https://doi.org/10.1111/j.1440-1746.2006.04194.x>.
84. Elvers KT, Wright SJ. 1995. Antibacterial activity of the anti-inflammatory compound ibuprofen. *Lett Appl Microbiol* 20:82–84. <https://doi.org/10.1111/j.1472-765X.1995.tb01291.x>.
85. Al-Janabi AA. 2011. Determination of antidermatophytic effects of non-steroidal anti-inflammatory drugs on Trichophyton mentagrophytes and Epidermophyton floccosum. *Mycoses* 54:e443–e448. <https://doi.org/10.1111/j.1439-0507.2010.01945.x>.
86. Domenico P, Salo RJ, Straus DC, Hutson JC, Cunha BA. 1992. Salicylate or bismuth salts enhance opsonophagocytosis of *Klebsiella pneumoniae*. *Infection* 20:66–72. <https://doi.org/10.1007/BF01711065>.
87. Sawai T, Hirano S, Yamaguchi A. 1987. Repression of porin synthesis by salicylate in *Escherichia coli*, *Klebsiella pneumoniae* and *Serratia marcescens*. *FEMS Microbiol Lett* 40:233–237. <https://doi.org/10.1111/j.1574-6968.1987.tb02031.x>.
88. Seoane AS, Levy SB. 1995. Characterization of MarR, the repressor of the multiple antibiotic resistance (mar) operon in *Escherichia coli*. *J Bacteriol* 177:3414–3419. <https://doi.org/10.1128/jb.177.12.3414-3419.1995>.
89. Dutta NK, Annadurai S, Mazumdar K, Dastidar SG, Kristiansen JE, Molnar J, Martins M, Amaral L. 2007. Potential management of resistant microbial infections with a novel non-antibiotic: the anti-inflammatory drug diclofenac sodium. *Int J Antimicrob Agents* 30:242–249. <https://doi.org/10.1016/j.ijantimicag.2007.04.018>.
90. Kruszewska H, Zareba T, Tyski S. 2012. Examination of antimicrobial activity of selected non-antibiotic medicinal preparations. *Acta Pol Pharm* 69:1368–1371.
91. Dastidar SG, Ganguly K, Chaudhuri K, Chakrabarty AN. 2000. The antibacterial action of diclofenac shown by inhibition of DNA synthesis. *Int J Antimicrob Agents* 14:249–251. [https://doi.org/10.1016/S0924-8579\(99\)00159-4](https://doi.org/10.1016/S0924-8579(99)00159-4).
92. Annadurai S, Guha-Thakurta A, Sa B, Dastidar SG, Ray R, Chakrabarty AN. 2002. Experimental studies on synergism between aminoglycosides and the antimicrobial anti-inflammatory agent diclofenac sodium. *J Chemother* 14:47–53. <https://doi.org/10.1179/joc.2002.14.1.47>.
93. Laudy AE, Mrowka A, Krajewska J, Tyski S. 2016. The influence of efflux pump inhibitors on the activity of non-antibiotic NSAIDs against gram-negative rods. *PLoS One* 11:e0147131. <https://doi.org/10.1371/journal.pone.0147131>.
94. Al-Janabi AS. 2009. In vitro and in vivo therapeutic activity of ibuprofen against dermatophytes. *Saudi Med J* 30:624–628.
95. Gagyor I, Bleidorn J, Kochen MM, Schmiemann G, Wegscheider K, Hummers-Pradier E. 2015. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. *BMJ* 351:h6544. <https://doi.org/10.1136/bmj.h6544>.
96. Yin Z, Wang Y, Whittell LR, Jergic S, Liu M, Harry E, Dixon NE, Kelso MJ, Beck JL, Oakley AJ. 2014. DNA replication is the target for the antibacterial effects of nonsteroidal anti-inflammatory drugs. *Chem Biol* 21:481–487. <https://doi.org/10.1016/j.chembiol.2014.02.009>.
97. Parvez M, Qhanya LB, Mthakathi NT, Kgosiemang IK, Bamal HD, Pagadala NS, Xie T, Yang H, Chen H, Theron CW, Monyaki R, Raselemane SC, Salewe V, Mongale BL, Matowane RG, Abdalla SM, Booi WI, van Wyk M, Olivier D, Boucher CE, Nelson DR, Tuszyński JA, Blackburn JM, Yu JH, Mashele SS, Chen W, Syed K. 2016. Molecular evolutionary dynamics of cytochrome P450 monooxygenases across kingdoms: special focus on mycobacterial P450s. *Sci Rep* 6:33099. <https://doi.org/10.1038/srep33099>.
98. Byrne ST, Denkin SM, Zhang Y. 2007. Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis. *J Antimicrob Chemother* 59:313–316. <https://doi.org/10.1093/jac/dkl486>.
99. Singh RP, Srivastava AK, Sharma SK, Nauriyal DC. 1998. Influence of *Escherichia coli* endotoxin induced fever on the pharmacokinetics and dosage regimen of oxytetracycline in cross-bred calves. *Acta Vet Hung* 46:95–100.
100. Kupferwasser LI, Yeaman MR, Shapiro SM, Nast CC, Sullam PM, Filler SG, Bayer AS. 1999. Acetylsalicylic acid reduces vegetation bacterial density, hematogenous bacterial dissemination, and frequency of embolic events in experimental *Staphylococcus aureus* endocarditis through antiplatelet and antibacterial effects. *Circulation* 99:2791–2797. <https://doi.org/10.1161/01.CIR.99.21.2791>.
101. Northover BJ, Subramanian G. 1962. Analgesic-antipyretic drugs as antagonists of endotoxin shock in dogs. *J Pathol Bacteriol* 83:463–468. <https://doi.org/10.1002/path.1700830217>.
102. Fletcher JR, Ramwell PW. 1977. Modification, by aspirin and indomethacin, of the haemodynamic and prostaglandin releasing effects of *E. coli* endotoxin in the dog. *Br J Pharmacol* 61:175–181. <https://doi.org/10.1111/j.1476-5381.1977.tb08402.x>.
103. Hinshaw LB, Solomon LA, Erdos EG, Reins DA, Gunter BJ. 1967. Effects of acetylsalicylic acid on the canine response to endotoxin. *J Pharmacol Exp Ther* 157:665–671.
104. Bernard GR, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP, Fulkerson WJ, Wright PE, Christman BW, Dupont WD, Higgins SB, Swindell BB. 1997. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. *N Engl J Med* 336:912–918. <https://doi.org/10.1056/NEJM199703273361303>.
105. Rosner JL, Chai TJ, Foulds J. 1991. Regulation of ompF porin expression by salicylate in *Escherichia coli*. *J Bacteriol* 173:5631–5638. <https://doi.org/10.1128/jb.173.18.5631-5638.1991>.
106. Hutsul JA, Worobec E. 1997. Molecular characterization of the *Serratia marcescens* ompF porin, and analysis of *S. marcescens* ompF and ompC osmoregulation. *Microbiology* 143(Pt 8):2797–2806. <https://doi.org/10.1099/00221287-143-8-2797>.
107. Begic S, Worobec EA. 2006. Regulation of *Serratia marcescens* ompF and ompC porin genes in response to osmotic stress, salicylate, temperature and pH. *Microbiology* 152:485–491. <https://doi.org/10.1099/mic.0.28428-0>.
108. Shann F. 1995. Antipyretics in severe sepsis. *Lancet* 345:338. [https://doi.org/10.1016/S0140-6736\(95\)90337-2](https://doi.org/10.1016/S0140-6736(95)90337-2).
109. Al-Bakri AG, Othman G, Bustanji Y. 2009. The assessment of the antibacterial and antifungal activities of aspirin, EDTA and aspirin-EDTA combination and their effectiveness as antibiofilm agents. *J Appl Microbiol* 107:280–286. <https://doi.org/10.1111/j.1365-2672.2009.04205.x>.
110. da Rocha Neto AC, Maraschin M, Di Piero RM. 2015. Antifungal activity of salicylic acid against *Penicillium expansum* and its possible mechanisms of action. *Int J Food Microbiol* 215:64–70. <https://doi.org/10.1016/j.ijfoodmicro.2015.08.018>.
111. Krystofova S, Varecka L, Vollek V, Grimova J, Betina V. 1994. Growth and conidiation of *Trichoderma viride* are affected by non-steroidal anti-inflammatory agents. *Folia microbiol (Praha)* 39:44–48. <https://doi.org/10.1007/BF02814528>.
112. Bandara M, Sankaridurg P, Zhu H, Hume E, Willcox M. 2016. Effect of salicylic acid on the membrane proteome and virulence of *Pseudomonas aeruginosa*. *Invest Ophthalmol Vis Sci* 57:1213–1220. <https://doi.org/10.1167/iovs.15-18990>.
113. English N, Hughes V, Wolf CR. 1996. Induction of cytochrome P-450 BM-3 (CYP 102) by non-steroidal anti-inflammatory drugs in *Bacillus megaterium*. *Biochem J* 316(Pt 1):279–283. <https://doi.org/10.1042/bj3160279>.